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AbsTrACT
Introduction The clinical effectiveness of a ’rule- out’ 
acute coronary syndrome (acs) strategy for emergency 
department patients with chest pain, incorporating a 
single undetectable high- sensitivity cardiac troponin 
(hs- cTn) taken at presentation, together with a non- 
ischaemic ecg, remains unknown.
Methods a randomised controlled trial, across eight 
hospitals in the UK, aimed to establish the clinical 
effectiveness of an undetectable hs- cTn and ecg (limit 
of detection and ecg discharge (loDeD)) discharge 
strategy. eligible adult patients presented with chest 
pain; the treating clinician intended to perform 
investigations to rule out an acs; the initial ecg was 
non- ischaemic; and peak symptoms occurred <6 hours 
previously. Participants were randomised 1:1 to either 
the loDeD strategy or the usual rule- out strategy. The 
primary outcome was discharge from the hospital within 
4 hours of arrival, without a major adverse cardiac event 
(Mace) within 30 days.
results Between June 2018 and March 2019, 632 
patients were randomised; 3 were later withdrawn. Of 
629 patients (age 53.8 (sD 16.1) years, 41% women), 
7% had a Mace within 30 days. For the loDeD strategy, 
141 of 309 (46%) patients were discharged within 
4 hours, without Mace within 30 days, and for usual 
care, 114 of 311 (37%); pooled adjusted Or 1.58 (95% 
ci 0.84 to 2.98). no patient with an initial undetectable 
hs- cTn had a Mace within 30 days.
Conclusion The loDeD strategy facilitates safe early 
discharge in >40% of patients with chest pain. clinical 
effectiveness is variable when compared with existing 
rule- out strategies and influenced by wider system 
factors.
Trial registration number isrcTn86184521.
InTroduCTIon
The number of patients attending emergency 
departments (EDs) worldwide continues to rise. 
Across England and Wales, there were over 
23 million attendances in 2017–2018, a rise of over 
20% in a decade.1 Chest pain makes up 6% of ED 
attendances in the UK and is the most common 
reason for emergency hospital admission.2 Many 
patients with chest pain have prolonged hospital 
stays during which they undergo testing to rule 
out acute myocardial infarction (AMI), yet 90% of 
patients are found to have a non- cardiac cause of 
chest pain.2 Prolonged assessment leads to increased 
costs and ED crowding.3
For patients with suspected cardiac chest pain, 
the diagnostic biomarker of choice is cardiac 
troponin, a marker of myocardial necrosis.4 High- 
sensitivity cardiac troponin (hs- cTn) assays have 
been developed, and very low concentrations can 
be measured.5 This has led to improved diagnostic 
accuracy earlier after chest pain onset and devel-
opment of rapid ‘rule- out’ strategies for low- risk 
patients.6–15 These strategies have predominantly 
been evaluated within observational cohorts, and a 
lack of high- quality interventional trial data means 
that the potential of hs- cTn assays to improve clin-
ical effectiveness in the rapid discharge of low- risk 
patients with chest pain admitted to the ED remains 
poorly understood.14
A rapid rule- out strategy incorporating a single 
undetectable (below the limit of detection (LoD)) 
hs- cTn taken at ED presentation, together with 
a normal ECG, has been extensively evaluated in 
observational studies.8–15 While this limit of detec-
tion and ECG discharge (LoDED) strategy main-
tains a high diagnostic accuracy for both AMI and 
major adverse cardiac events (MACEs), across 
populations, the proportion of patients actually 
discharged after a single blood test, and conse-
quently its clinical and cost effectiveness, remains 
unknown.3 14 Due to concerns about reporting 
imprecision, the undetectable cut- off has not been 
approved for use by the US Food and Drug Admin-
istration,16 while in Europe, consensus guidelines 
include caveats to its clinical use. European Society 
of Cardiology (ESC) guidelines recommend that the 
undetectable cut- off is only used if blood sampling 
occurs more than 3 hours after chest pain onset, and 
UK National Institute of Health and Care Excel-
lence guidelines suggests it should be confined to 
low- risk patients identified using a validated risk 
score.17 18 This may explain why around only 3% of 
hospitals within the UK use the undetectable cut- off 
in clinical practice.19
We aimed to determine whether the LoDED 
strategy, when used irrespective of chest pain 
onset time, without risk scores and across different 
hs- cTn assays, would increase the rate of safe early 
discharge from hospital in patients with suspected 
cardiac chest pain, when embedded within routine 
ED practice, and without an increase in healthcare 
costs.
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Figure 1 ConsolidatedStandards of Reporting Trials diagram. ACS, acute coronary syndrome; LoD, limit of detection; LoDED, limit of detection and 
ECG discharge.
MeThods
study design and participants
The LoDED strategy versus usual care in adult patients with 
chest pain attending the ED trial was a prospective randomised 
open label blinded endpoint parallel group trial that aimed to 
assess the clinical effectiveness of the LoDED strategy in adult 
patients presenting to the ED with suspected cardiac chest 
pain in eight secondary and tertiary hospitals across England 
and Wales. Patients were eligible for recruitment if they were 
aged ≥18 years; presented to the ED with chest pain and trig-
gered a suspected cardiac chest pain investigation pathway (ie, 
the treating clinician intended to perform investigations to 
rule out an acute coronary syndrome); had a non- ischaemic 
ECG (no new T- wave inversion of >3 mm or ST depression of 
>1 mm as judged by the treating clinician); and peak symptoms 
occurred <6 hours prior to ED presentation. Exclusion criteria 
are described in the published trial protocol and included in 
the Consolidated Standards of Reporting Trials (CONSORT) 
diagram (figure 1).20
randomisation and blinding
Patients were randomised to evaluation with either the LoDED 
strategy (intervention) or the usual rule- out strategy in that 
site (control) in a 1:1 ratio, before initial hs- cTn results were 
known to the treating clinician. Randomisation was under-
taken through a web- based portal, stratified by site and mini-
mised by age and sex.
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Table 1 Summary of usual rule- out strategies (control) by site
site (All uK)
high- sensitivity troponin 
assay
risk stratification tool and 
definition of low- risk
Troponin assay sampling 
times for low- risk patients
Troponin assay result to allow discharge if 
low- risk
Sites not using the LoD cut- off within usual rule- out strategies
Royal United Hospital, Bath Roche Elecsys hs- cTnT* GRACE28 score 
<1.5% six month mortality
Presentation and after 6 hours 
(or 6 hours from onset of pain)
Both results <14 ng/L OR 14–30 ng/L and no 
change >20% between tests
Southmead Hospital, Bristol Roche Elecsys hs- cTnT* TIMI score <2 Presentation and after 2 hours Both results <14 ng/L OR 14–30 ng/L and no 
change >20% between tests
Derriford Hospital, Plymouth Abbott Architect hs- cTnI† HEART26 score ≤3 Presentation and after 3 hours Both results <99th percentile (sex- specific)†
University Hospital, 
Southampton
Beckman- Coulter Access 
hs- cTnI‡
TIMI29 score <2 Presentation and after 3 hours Both results <18 ng/L
Sites using the LoD cut- off within usual rule- out strategies
University Hospital of Wales, 
Cardiff
Abbott Architect hs- cTnI† HEART26 score ≤2 Presentation and after 3 hours Presentation <2 ng/L (LoD) and >2 hours after 
symptom onset
OR both results <99th percentile (sex- specific)†
Royal Devon and Exeter 
Hospital, Exeter
Roche Elecsys hs- cTnT* Absence of ECG changes and 
unstable angina symptoms
Presentation and after 1 hour Presentation <5 ng/L (LoD) and >3 hours after 
symptom onset OR both results <14 ng/L
Royal London Hospital, Barts 
Health NHS Trust, London
Roche Elecsys hs- cTnT* HEART26 score ≤3 Presentation and after 3 hours Presentation <5 ng/L (LoD) OR both results 
<14 ng/L
Royal Berkshire Hospital, 
Reading
Roche Elecsys hs- cTnT* HEART26 score ≤3 Presentation and after 1 hour Presentation <5 ng/L (LoD) and >3 hours after 
symptom onset OR both results <14 ng/L
*Roche Elecsys hs- cTnT. This assay has a 99th percentile value of 14 ng/L and LoD of 5 ng/L.
†Abbott Architect hs- cTnI. This assay has 99th percentile value of 34 ng/L in men and 16 ng/L in women and LoD of 2 ng/L.
‡Beckman- Coulter Access hs- cTnI. This assay has a 99th percentile value of 18 ng/L and LoD of 2 ng/L.
GRACE, Global Registry of Acute Coronary Events; HEART, history, ECG, age, risk factors, troponin; hs- cTnI, high- sensitivity cardiac troponin I; hs- cTnT, high- sensitivity cardiac 
troponin T; LoD, limit of detection; TIMI, Thrombolysis In Myocardial Infarction.
Procedures
Cardiac troponin testing and measurement
All participants had a blood sample taken for hs- cTn measure-
ment at, or shortly after, ED arrival as part of their standard 
clinical assessment. Where repeat hs- cTn sampling was required, 
this was undertaken according to local guidelines (table 1) and 
not controlled for trial purposes.
Clinical blood samples were analysed, in real- time, locally in 
central hospital laboratories for either the Roche Elecsys high- 
sensitivity cardiac troponin T (hs- cTnT) assay, Abbott Architect 
high- sensitivity cardiac troponin I (hs- cTnI) or Beckman Coulter 
Access hs- cTnI (further assay details in table 1).
Trial interventions
LoDED Strategy (intervention)
Participants randomised to the LoDED strategy were eligible for 
discharge if their ECG was non- ischaemic; a single hs- cTn test 
taken at presentation (and irrespective of the symptom onset 
time) was undetectable for the assay used at that study site; 
and there was no ongoing clinical concern. Any participant not 
fulfilling these discharge criteria reverted to the usual rule- out 
strategy at that study site.
Usual rule-out strategies (control)
Table 1 summarises the usual rule- out strategies in use across the 
eight sites. No sites used identical strategies; this heterogeneity 
accords with the findings of a cross- sectional survey of English 
hospitals and therefore reflects current practice.19
Clinical management, data collection and follow- up processes 
are detailed in the supplementary material and in the published 
protocol.20
outcomes
The primary outcome was successful early discharge, defined as 
discharge from hospital within 4 hours of ED arrival, without 
a MACE occurring within 30 days. A time point was chosen 
for the primary outcome, rather than admission/discharge rate, 
because hospital admission is defined differently in different 
hospitals. This approach has been used in previous randomised 
trials evaluating the clinical effectiveness of rule- out strate-
gies.7 21 The time point of 4 hours was selected to reflect the 
NHS 4- hour ED standard. Such targets have been used inter-
nationally to provide an impetus to manage patients in a timely 
manner in an emergency setting.1 The safety endpoint of MACE 
occurring within 30 days was defined as cardiac death, type I 
AMI or emergency revascularisation occurring within 30 days of 
ED attendance (including the index presentation). Type I AMI 
was defined according to the Fourth Universal definition (a rise 
and/or fall of troponin above the 99th percentile).4 A significant 
rise and/or fall was defined as an absolute change in troponin 
over time of at least half the 99th percentile value of the assay 
in use.22 Primary outcomes were adjudicated by an independent 
expert panel comprising a senior emergency physician and cardi-
ologist blinded to both participants’ allocated groups and initial 
hs- cTn results. Secondary outcomes are listed in the supplement.
statistical analysis
The statistical and health economic analysis are described in 
detail in the supplementary material. Briefly, for the statistical 
analysis of the primary outcome, an intention- to- diagnose 
logistic regression analysis, adjusting for age and sex using all 
those randomised with complete data, was conducted by centre. 
As expected, usual care pathways differed between sites, and 
the proportion of patients discharged within 4 hours varied, 
which influenced observed treatment effects at each centre. 
Meta- analysis methodology was used to produce an overall OR 
and between- centre heterogeneity examined using the Q and I2 
statistic. Potential reasons for heterogeneity were investigated 
further for sites with and without the undetectable cut- off in 
usual care and by hs- cTn assay type. Kaplan- Meier- type graphs 
illustrate the relationship between length of hospital stay.
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Table 2 Patient demographics and risk characteristics
usual rule- out 
strategy (n=313)
Loded strategy 
(n=316)
All patients 
(n=629)
Age (years), mean (SD) 53.6 (16.2) 54.0 (16.2) 53.8 (16.1)
Sex       
  Women (%) 127 (41) 129 (41) 256 (41)
  Men (%) 186 (59) 187 (59) 373 (59)
Ethnic origin (%)*       
  White 277 (89) 277 (88) 554 (88)
Chest pain history (clinician reported)† (%)
  Slightly suspicious 176 (56) 171 (54) 347 (55)
  Moderately suspicious 112 (36) 111 (35) 223 (36)
  Highly suspicious 25 (8) 34 (11) 59 (9)
Prior history of coronary artery 
disease (%)
41 (13) 40 (13) 81 (13)
Known risk factors (%)       
  Hypercholesterolaemia 48 (15) 55 (17) 103 (16)
  Hypertension 86 (28) 82 (26) 168 (27)
  Diabetes (treated) 31 (10) 34 (11) 65 (10)
  Current smoking 54 (17) 54 (17) 108 (17)
  Family history of coronary artery 
disease (first- degree relative 
under the age of 65 years)
67 (21) 71 (23) 138 (22)
TIMI score,‡ median (IQR) 0 (0–1) 0 (0–1) 0 (0–1)
  TIMI score 0 (%) 175 (57.6) 176 (57.3) 351 (57.5)
  TIMI score 1 (%) 60 (19.7) 63 (20.5) 123 (20.1)
  TIMI score ≥2 (%) 69 (22.7) 68 (22.2) 137 (22.4)
HEART score,§ median (IQR) 2 (1–4) 2 (1–4) 2 (1–4)
  HEART score 0–3 (%) 213 (71) 211 (69) 424 (70)
  HEART score 4–6 (%) 75 (25) 83 (27) 128 (26)
  HEART score ≥7 (%) 13 (4) 11 (4) 24 (4)
Chest pain onset to arrival in ED 
(hours), median (IQR)
2.5 (1.6–3.9) 2.2 (1.4–3.4) 2.3 (1.5–3.6)
Chest pain onset to arrival in ED 
(hours) (range)¶
0.02–178.4 0.02–120.5 0.02–178.4
Chest pain onset to first hs- cTn 
sample collection (hours) (median 
(IQR))
3.3 (2.4–4.7) 3.2 (2.2–4.5) 3.3 (2.3–4.5)
Chest pain onset to first hs- cTn 
sample collection (hours) (range)¶
0.2–178.6 0.5–121.4 0.2–178.6
Chest pain onset to first hs- cTn sample collection categorised by minutes (%)
  0–60 min 9 (3) 4 (1) 13 (2)
  61–120 min 34 (12) 54 (18) 88 (15)
  121–180 min 85 (29) 76 (26) 161 (28)
  >181 min 161 (56) 162 (55) 323 (55)
*Data missing for one patient.
†Clinicians were asked to grade level of suspicion after taking a history according to 
definitions used within the HEART score (see further).26 A highly suspicious history included 
all of central chest discomfort with radiation to the jaw/arms precipitated by exertion and 
relieved by rest or nitrates. A moderately suspicious history included some highly suspicious 
features but will have some other atypical features, such as right- sided pain, burning pain or 
pain that is worse on deep inspiration. A slightly suspicious history did not have any highly 
suspicious features but by definition of being involved in the trial, the treating clinician felt 
the patient warranted testing to rule out a cardiac cause for chest pain.
‡TIMI score.29 Data available in 611/629 cases.
§HEART: data available in 606/629 cases.26
¶Refers to chest pain onset time, rather than peak symptoms. Note patients were excluded if 
peak symptoms occurred >6 hours prior to ED presentation.
ED, emergency department; HEART, History, ECG, Age, Risk factors, Troponin; hs- cTn, high- 
sensitivity cardiac troponin; LoDED, limit of detection and ECG discharge; TIMI, Thrombolysis 
In Myocardial Infarction.
sample size
The target sample size was based on both observational and 
interventional data.7 13–15 For the overall population, we antic-
ipated 8% of participants would be discharged within 4 hours 
using usual care and at least 17% using the LoDED strategy. 
Therefore, the trial was powered to detect a 9% difference 
between early discharge rates with 90% power and two- sided 
alpha of 0.05. This required 282 patients in each group with 
primary outcome data. Allowing for a 95% follow- up rate, a 
total recruitment target of 594 participants was set.
Patient and public involvement
Patient and public involvement occurred at all stages of trial 
design and conduct. A patient advisory group (PAG) oversaw 
development and approval of patient- facing materials. The PAG 
supported the interpretation of results and approved the final 
manuscript submission.
resuLTs
In total, 632 patients were randomised between 4 June 2018 
and 4 March 2019. Three patients were later withdrawn; one 
had no record of consent and two were randomised in error. All 
remaining 629 patients were successfully monitored for 30 days. 
A total of 316 patients were allocated to the LoDED strategy and 
313 to usual care (figure 1). The baseline characteristics were 
well balanced between groups (table 2). The cohort was predom-
inantly men (59%), of white British ethnicity (88%), with a 
mean age of 53.8 years, and were at low risk of cardiac disease. 
Patients presented at a median of 2.3 hours (IQR 1.5–3.6 hours) 
after chest pain onset and the first hs- cTn sample was drawn at 
a median of 3.3 hours (IQR 2.3–4.5) after chest pain onset. Of 
the 629 patients, 42 (7%) had a MACE within 30 days (table 3).
Primary outcome
Data were available for the primary outcome in 620/629 patients. 
Discharge time was not recorded for 14 patients, but for five of 
these, their length of stay was over 4 hours. When allocated to 
the LoDED strategy, 141 of 309 (46%) were discharged within 
4 hours of arrival, without subsequent 30- day MACE, and for 
usual rule- out strategies, 114 of 311 (37%) (table 3); pooled OR 
1.58 (95% CI 0.84 to 2.98). The Kaplan- Meier- type length of 
stay curve illustrates improved discharge rates using the LoDED 
strategy, which persisted until 8 hours after patient arrival 
(figure 2).
Figure 3 demonstrates significant heterogeneity between sites 
for the primary outcome (I2=61%, p=0.01 for Q test of hetero-
geneity), which was only partially explained by the control 
rule- out strategies in use. For sites using the undetectable cut- off 
within usual care, the pooled OR was 0.93 (95% CI 0.54 to 
1.59, I2=0.0%, p=0.58 for Q test). For sites not using the unde-
tectable cut- off within usual care, the pooled OR for the primary 
outcome was 2.87 (95% CI 1.07 to 7.69, I2=67%, p=0.03 for 
Q test). This positive treatment effect was driven by only two 
sites, Bristol (OR 8.33, 95% CI 2.82 to 24.64) and Southampton 
(OR 6.01, 95% CI 1.19 to 30.44), with no effect seen in the 
remaining two sites not using the LoD within usual care, Bath 
(OR 1.59, 95% CI 0.60 to 4.25) and Plymouth (OR 1.14, 95% CI 
0.42 to 3.06). Kaplan- Meier- type length of stay curves for each 
site are included in online supplementary figures 1–8. Clinical 
outcomes by group allocation and site are shown in table 3. A 
subgroup analysis of patients with an initial undetectable hs- cTn 
is detailed in figure 4 and in the online supplementary material. 
Resource use data are described in table 4, together with mean 
per- patient costs by category. Comparative costs are described in 
detail in the online supplementary material.
Acceptability and adherence to the Loded strategy
Interviews with 11 patients from four sites and two focus 
groups with 20 ED professionals and general practitioners were 
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Table 3 Clinical outcomes and comparative costs
usual rule- out strategy Loded strategy
All patients
Patients successfully discharged within 4 hours (1° outcome) (%) 114/311 (37) 141/309 (46) OR 1.58 (95% CI 0.84 to 2.98)*
MACEs at 30 days (%) 17/313 (5) 25/316 (8) OR 1.50 (95% CI 0.76 to 3.02)†
MACEs in patients discharged within 4 hours (%) 1/115 (1) 0/141 (0) –
Median time to discharge (hours) (IQR) 5.0 (3.4–7.4) 4.4 (3.2–6.8) All patients: 4.8 (3.3–7.0)
Patient satisfaction score, median (IQR)‡ 50 (44–55) 51 (44–55) –
Mean secondary care costs up to 30 days post discharge (95% CI)§ £527 (£391 to £720)¶ £429 (£302 to £651)¶ Unadjusted incremental cost
£98 (£−131 to £332)**
Adjusted incremental cost:
£151 (£−34 to £336)††
Patients with an initial hs- cTn below the Lod ‡‡
Patients with an initial hs- cTn below the LoD (%) 133/304 (44) 141/307 (46) All patients: 274/611 (45)
Patients with an initial hs- cTn below the LoD successfully discharged within 4 hours (%) 68/132 (52) 97/137 (71) OR 2.51 (95% CI 0.76 to 8.25)†
MACEs at 30 days 0 0 –
Median time to discharge (hours) (IQR) 4.0 (3.0–5.7) 3.5 (2.7–4.3) All patients: 3.7 (2.8–5.2)
Mean primary and secondary care costs up to 30 days post discharge (95% CI)§§ £213 (£172 to £273)¶ £184 (£153 to 243)¶ Incremental cost:
£29 (−£33 to £99)**
site variation
Patients successfully discharged within 4 hours (1° outcome) (%)       
Royal United Hospital, Bath 16/34 (47) 20/35 (57)   
Southmead Hospital, Bristol 6/60 (10) 25/60 (42)   
Derriford Hospital, Plymouth 10/46 (22) 11/45 (24)   
University Hospital, Southampton 3/27 (11) 9/26 (35)   
University Hospital of Wales, Cardiff 11/17 (65) 11/21 (52)   
Royal Devon and Exeter Hospital, Exeter 21/49 (43) 20/48 (42)   
Royal London Hospital, Barts Health NHS Trust, London 8/34 (24) 11/33 (33)   
Royal Berkshire Hospital, Reading 39/44 (89) 34/41 (83)   
Median time to discharge (hours) (IQR)     
Royal united Hospital, Bath 4.4 (3.1 to 9.7) 3.5 (2.5 to 6.6)   
Southmead Hospital, Bristol 5.6 (4.7 to 7.1) 4.5 (3.2 to 6.1)   
Derriford Hospital, Plymouth 6.1 (4.3 to 7.0) 5.5 (4.1 to 7.1)   
University Hospital, Southampton 5.9 (4.9 to 8.3) 5.7 (3.4 to 6.2)   
University Hospital of Wales, Cardiff 3.8 (2.8 to 6.5) 4.0 (3.1 to 5.8)   
Royal Devon and Exeter Hospital, Exeter 5.1 (3.5 to 26.5) 5.3 (3.5 to 28.4)   
Royal London Hospital, Barts Health NHS Trust, London 5.4 (4.1 to 9.1) 6.4 (3.9 to 8.2)   
Royal Berkshire Hospital, Reading 2.8 (2.5 to 3.4) 3.2 (2.5 to 3.8)   
*Pooled adjusted OR.
†Pooled unadjusted OR.
‡The Group Health Association of America Satisfaction Questionnaire was completed on discharge (online supplementary table S4).27 Scores out of 5 were summed for each of 11 questions, giving 
a maximum score of 55. 352/629 responses received.
§Data were available to calculate secondary care costs in 295/313 patients in the usual care arm and 295/316 in the intervention. The unit cost template for this analysis is available in the online 
supplementary material.
¶Mean cost with 95% bias corrected and accelerated CIs.
**Bootstrap mean difference with bias 95% bias corrected and accelerated CIs.
††Adjusted predicted mean cost difference (95% Confidence Intervals), generalised linear model (GLM) with a log link function and inverse gaussian family.
‡‡Data missing for 18 patients on the initial troponin result: 15 samples were haemolysed and three were lost.
§§Data were available to calculate primary and secondary care costs in 125/133 patients in the usual care arm 122/141 in the intervention. The unit cost template for this analysis is available in 
the online supplementary material.
Hs- cTn, high- sensitivity cardiac troponin; LoD, limit of detection; LoDED, limit of detection and ECG discharge; MACE, major adverse cardiac event.
conducted. From the qualitative interviews, patients were not 
anxious about the new strategy, trusted the clinicians’ judge-
ment and welcomed the opportunity to be discharged sooner. 
Clinicians were more sceptical about discharging patients early 
in case they missed something and awaited the trial results 
to reassure them that there were no adverse consequences of 
discharging patients sooner (a full qualitative report has been 
submitted for publication and is available on request to the 
authors). Despite this finding, 88% (95%CI 81% to 93%) of 
patients allocated to the LoDED strategy who had an initial 
hs- cTn below the LoD were discharged from hospital in accor-
dance with the strategy.
dIsCussIon
We evaluated whether the use of a rapid rule- out strategy 
based on a single undetectable hs- cTn test taken on arrival at 
the ED (irrespective of chest pain onset time), together with a 
normal ECG (the LoDED strategy), increased the rate of safe, 
early discharge. When embedded within existing rule- out 
strategies in use across eight sites, the LoDED strategy facili-
tated discharge within 4 hours in over 40% of all patients and, 
importantly, no patient discharged with an initial undetectable 
hs- cTn had a MACE before 30 days. This accords with findings 
from multiple observational studies that the LoDED strategy is 
safe and provides clinicians with an opportunity to discharge 
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Figure 2 Kaplan- Meier- type length of stay curve by group allocation 
(intention to treat). LoDED, limit of detection and ECG discharge.
Figure 3 Forest plot for the primary outcome of successful early discharge. LoDED, limit of detection and ECG discharge.
Figure 4 Kaplan- Meier- type length of stay curve for patients with 
an initial high- sensitivity cardiac troponin below the limit of detection. 
LoDED, limit of detection and ECG discharge.
low- risk patients based on a single undetectable hs- cTn result.8–15 
However, when compared with existing rule- out strategies 
which use hs- cTn assays as recommended by consensus guide-
lines,19 20 the LoDED strategy did not show a difference in the 
rate of safe early discharge, even in those patients with an initial 
undetectable hs- cTn. There was also no difference in healthcare 
costs between the two strategies.
There are a number of potential explanations for these find-
ings. First, the proportion of patients discharged within 4 hours 
across control strategies (37%) was much greater than the 
8% estimated in our power calculation, which was based on 
an interventional study of a testing strategy of 0 and 2 hours 
undertaken 5 years prior to designing this trial (the primary 
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Table 4 Total resource use and mean per- patient costs by category
All patients
Patients with an initial 
undetectable hs- cTn
Total resource use, n (%*) or 
mean cost per person (sd)
Total resource use, n (%*) or 
mean cost per person (sd)
usual rule- out 
strategy
(n=295)
Loded strategy
(n=295)
usual rule- out 
strategy
(n=125)
Loded strategy
(n=122)
Second or third hs- cTn 
test†
168 (57) 124 (42) 54 (43.2) 12 (10)
Second ECG† 50 (17) 59 (20) 17 (14) 25 (20)
Subsequent nights in 
hospital
113 (11) 241 (13) 8 (3) 47 (3)
Cardiac procedures 
(heart bypass, stent 
and pacemaker)
9 (3) 15 (5) 0 0
Additional 
cardiac tests‡ (eg, 
echocardiogram and 
exercise tolerance test)
– – 9 (5) 15 (11)
Primary care contacts – – 105 (49) 107 (53)
Subsequent ED 
contacts
– – 10 (6) 21 (10)
Outpatient contacts – – 24 (16) 29 (19)
Costs
Initial hospital stay 
(Including hs- cTn test 
and ECG)
£210 (£20) £222 (£22) £98 (£7) £91 (£9)
Cardiac procedures 
(heart bypass, stent 
and pacemaker)
£163 (£65) £221 (£63) £0 £0
Subsequent hospital 
stay
£56 (£10) £84 (£14) £14 (£7) £24 (£13)
Additional 
cardiac tests‡ (eg, 
echocardiogram and 
exercise tolerance test)
– – £6 (£3) £13 (£4)
Primary care – – £26 (£5) £26 (£4)
Subsequent ED 
contacts
– – £13(£6) £27 (£11)
Outpatient contacts – – £27 (£6) £31 (£6)
*Percentage of total patients with at least one interaction or resource use.
†Captures additional resources use (all participants had at least one hs- cTn test and one ECG test).
‡Additional tests were (% undergoing test in the whole cohort) echocardiogram (4.9%), exercise 
tolerance test (0.8%), stress echocardiogram (0.4%), CT coronary angiogram (0.8%), invasive coronary 
angiogram (0.8%), 24- hour cardiac monitor (0.8%) and abdominal ultrasound (0.4%).
ED, emergency department; hs- cTn, high- sensitivity cardiac troponin; LoDED, limit of detection and ECG 
discharge.
outcome for that trial was successful discharge within 6- hour of 
arrival; data on 4- hour discharge rates were provided through 
personal communication with the trial statistician).7 This may 
reflect an improved clinical understanding of the use of rapid 
rule- out strategies to facilitate early discharge and subsequent 
guideline recommendations that the undetectable cut- off can be 
used in clinical practice, although with caveats.17 18 Contamina-
tion, whereby clinicians simply applied the LoDED strategy to 
those patients allocated to usual care, is also possible. Second, 
we observed considerable heterogeneity between sites, with 
some sites demonstrating a potential for reduced effective-
ness of the intervention strategy compared with usual care. 
We demonstrated improvements in the primary outcome at 
some sites where the undetectable cut- off was not already in 
use, as per guideline recommendations. However, even when 
accounting for these control strategy differences, significant 
heterogeneity remained. This is an important finding and may 
reflect local culture, in terms of which patients are selected for 
rule- out testing, and the high clinical intensity of the ED, which 
are beyond the rule- out strategy itself. Third, we undertook this 
study, in which discharge within 4 hours was a component of 
the primary outcome, during a time period when performance 
against the 4- hour standard for all ED patients has been at its 
worst for a decade.1 Given that we observed separation on the 
Kaplan- Meier- type length of stay curves between usual care 
and the LoDED strategy up to 8 hours after ED attendance, our 
findings may reflect poor performance against this standard, 
rather than performance of the rule- out strategy itself.
Despite being available for nearly a decade, there are very 
few interventional trials evaluating the clinical effectiveness 
or cost- effectiveness of hs- cTn assays in the rapid discharge of 
patients with chest pain admitted to the ED. One randomised 
controlled trial of over 3000 participants evaluating the ESC- 
recommended Roche hs- cTnT assay of 0 and 1 hour, rule- out 
strategy demonstrated improved clinical effectiveness in terms 
of rapid discharge from the ED, but compared this strategy to 
a control group where contemporary cut- offs were used, which 
may have inflated the results.23
Our trial has several strengths that distinguish it from prior 
studies and extend the generalisability of the findings. First, we 
tested a strategy that does not rely on a risk score. Numerous risk 
scores such as thrombolysis in myocardial infarction, history, 
ECG, age, risk factors, troponin and troponin- only Manchester 
acute coronary syndromes have been evaluated and shown 
promise in observational studies.24 25 However, when tested 
within interventional trials, poor adherence by clinicians has 
limited their clinical effectiveness when applied to practice.7 26 
Our results demonstrate good adherence to the LoDED strategy, 
suggesting clinicians would be willing to follow its recommenda-
tions when used in routine care. Second, one of the remaining 
controversies in the use of the undetectable cut- off is in patients 
who present early after chest pain onset.14 By excluding patients 
who presented over 6 hours from chest pain onset, we have 
tested the LoDED strategy in a population where around 45% 
of patients had their first sample drawn within 3 hours of chest 
pain onset. Given there were no 30- day MACEs in patients with 
an initial undetectable troponin in either arm of the trial, this 
provides reassurance to clinicians that the LoDED strategy can 
be used irrespective of chest pain onset time. However, clinical 
judgement should be used to ascertain the need for serial testing 
in very early presenters. Third, previous trials have tested hs- cTn 
assays provided by a single manufacturer.23 This approach can 
have significant limitations in terms of generalisability because 
hospitals may have limited opportunity to change assays. By 
applying the LoDED strategy across the three different troponin 
assays in which the undetectable cut- off has been evaluated in 
observational studies, we have enhanced the generalisability of 
our findings.8–15
Other study limitations include a trial design that assessed 
the clinical effectiveness of the LoDED strategy, rather than 
comparing safety between the intervention and control arms. 
It is possible that some patients discharged according to the 
LoDED strategy may have developed a subsequent subclinical 
rise in troponin after discharge. It is known that hs- cTn eleva-
tions above the undetectable cut- off may have prognostic impli-
cations when follow- up periods are extended beyond a year.27 
Prognostic implications have not been addressed in our trial. 
Finally, despite randomising participants prior to hs- cTn results 
being known, the population demographics suggest this is a low- 
risk chest pain population. We excluded patients with ischaemic 
ECG findings, which may explain the low- risk demographics. 
However, the trial sample had lower- risk demographics than 
an unselected observational study, which applied the same ECG 
exclusion criteria.8 Therefore, it is possible that a degree of 
patient selection occurred, and the study findings can only be 
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applied to patients with chest pain deemed low risk by treating 
clinicians.
We have shown that a rule- out strategy based on an initial 
undetectable hs- cTn test, normal ECG and no ongoing clinical 
concern (LoDED), facilitates the safe early discharge of over 
40% of patients with chest pain, without an increase in health-
care costs. However, the clinical effectiveness of such a strategy 
is limited when compared with existing rule- out strategies, espe-
cially those that already incorporate the undetectable cut- off. In 
addition, the clinical effectiveness of early rule- out strategies is 
likely to be undermined by a range of system factors such as 
prolonged ED waiting times and crowding.
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Key messages
What is already known on this subject?
 ► Numerous cohort studies, systematic reviews and meta- 
analyses suggest that patients with an undetectable 
high- sensitivity cardiac troponin (hs- cTn) concentration at 
presentation to the emergency department (ED) are at low- 
risk of 30- day major adverse cardiac events. This finding has 
been repeated across different troponin assays. However, 
a lack of interventional trial data means that the clinical 
effectiveness of embedding this rule- out strategy within 
routine practice is unknown.
What might this study add?
 ► Although the limit of detection (LoD) strategy facilitated the 
safe early discharge of over 40% of low- risk patients with 
chest pain, clinical effectiveness was not statistically different 
from usual care strategies that already incorporate high- 
sensitivity troponin tests. This finding brings into question 
existing observational evidence and may, in part, be due to 
factors beyond the strategy itself, such as the high clinical 
intensity of the ED, which has an important effect on the 
ability of clinicians to facilitate early discharge.
how might this impact on clinical practice?
 ► The LoD strategy is safe and provides clinicians with an 
opportunity to discharge low- risk patients based on a single 
undetectable hs- cTn result taken at presentation to the ED. 
However, clinicians should be mindful of the importance of 
clinical judgement in patients presenting early after chest 
pain onset, and in some centres the strategy may not lead 
to improved clinical effectiveness. Long- term prognostic 
implications of this strategy have not been addressed in this 
trial.
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